[February 17, 2014] |
 |
Neurovive Pharmaceutical: NeuroVive Treats Final Patient in European Phase III Trial on CicloMulsion®
STOCKHOLM --(Business Wire)--
Regulatory News:
NeuroVive Pharmaceutical AB (publ)(STO:NVP), a leading mitochondrial
medicine company, has reported that the last of a total of 972 patients
have now been enrolled and treated in its ongoing European phase III
trial (CIRCUS), in which half of patients received the company's
pharmaceutical CicloMulsion® for treating reperfusion injury coincident
with myocardial infarction.
"We've now reached a major milestone in the European cardiac study on
NeuroVive's product CicloMulsion®. The final patient was enrolled and
treated in the study on 16 February, and the trial will now be followed
up for a one-year period, as it finally closes for data analysis.
Enrolment of patients to the trial went well, and we're satisfied with
how it has followed our original plan so far," commented NeuroVive's CEO
Mikael Brönnegård.
About NeuroVive
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine
compny, is developing a portfolio of products to treat acute
cardiovascular and neurological conditions through mitochondrial
protection. These medical conditions are characterized by a pressing
medical need and have no approved pharmaceutical treatment options at
present. NeuroVive's products CicloMulsion® (heart attack) and
NeuroSTAT® (traumatic brain injury) are currently being evaluated in
phase III and phase II studies, respectively. NeuroVive's research
programs also include products for the treatment of anti-viral
indications (Hepatitis B/C), brain cell injury in stroke patients, and
drug candidates for cellular protection and treating
mitochondria-related energy regulation diseases. NeuroVive's shares are
listed on NASDAQ OMX, Stockholm, Sweden.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: + 46 (0)46 888 83 48, info@neurovive.se,
www.neurovive.se
NeuroVive Pharmaceutical AB (publ) is required to publish the
information in this news release under The Swedish Securities Market
Act. The information was submitted for publication on 17 February 2014,
at 8:45 a.m. CET.
This information was brought to you by Cision http://news.cision.com

[ Back To TMCnet.com's Homepage ]
|